The stock of Portage Biotech Inc (NASDAQ: PRTG) has decreased by -10.70 when compared to last closing price of 9.25.Despite this, the company has seen a gain of 102.95% in its stock price over the last five trading days. benzinga.com reported 2025-03-28 that Portage Biotech Inc. PRTG on Thursday presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, at the 2025 European Lung Cancer Congress.
Is It Worth Investing in Portage Biotech Inc (NASDAQ: PRTG) Right Now?
PRTG has 36-month beta value of 0.97. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for PRTG is 0.16M, and currently, short sellers hold a 8.64% ratio of that float. The average trading volume of PRTG on April 02, 2025 was 610.48K shares.
PRTG’s Market Performance
PRTG’s stock has seen a 102.95% increase for the week, with a 99.52% rise in the past month and a 57.03% gain in the past quarter. The volatility ratio for the week is 22.76%, and the volatility levels for the past 30 days are at 10.91% for Portage Biotech Inc The simple moving average for the past 20 days is 66.02% for PRTG’s stock, with a 75.00% simple moving average for the past 200 days.
Analysts’ Opinion of PRTG
Many brokerage firms have already submitted their reports for PRTG stocks, with Oppenheimer repeating the rating for PRTG by listing it as a “Outperform.” The predicted price for PRTG in the upcoming period, according to Oppenheimer is $26 based on the research report published on July 18, 2022 of the previous year 2022.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see PRTG reach a price target of $32. The rating they have provided for PRTG stocks is “Buy” according to the report published on March 07th, 2022.
Oppenheimer gave a rating of “Outperform” to PRTG, setting the target price at $30 in the report published on September 21st of the previous year.
PRTG Trading at 75.92% from the 50-Day Moving Average
After a stumble in the market that brought PRTG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.10% of loss for the given period.
Volatility was left at 10.91%, however, over the last 30 days, the volatility rate increased by 22.76%, as shares surge +94.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +101.46% upper at present.
During the last 5 trading sessions, PRTG rose by +102.95%, which changed the moving average for the period of 200-days by +60.64% in comparison to the 20-day moving average, which settled at $4.98. In addition, Portage Biotech Inc saw 59.77% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PRTG starting from Allan L. Shaw, who proposed sale 882 shares at the price of $5.39 back on Oct 03 ’24. After this action, Allan L. Shaw now owns shares of Portage Biotech Inc, valued at $4,754 using the latest closing price.
Allan L. Shaw, the Affiliate of Portage Biotech Inc, proposed sale 10,761 shares at $7.17 during a trade that took place back on Sep 27 ’24, which means that Allan L. Shaw is holding shares at $77,156 based on the most recent closing price.
Stock Fundamentals for PRTG
The total capital return value is set at -6.41. Equity return is now at value -194.84, with -136.43 for asset returns.
Based on Portage Biotech Inc (PRTG), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -349.79. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -733.94.
Currently, EBITDA for the company is -18.2 million with net debt to EBITDA at 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.08.
Conclusion
To put it simply, Portage Biotech Inc (PRTG) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
